Add Yahoo as a preferred source to see more of our stories on Google. Invivyd had also attempted to attain regulatory approval for pemivibart.Credit: Design_Cells via Shutterstock. (Design_Cells via ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital ...

Interim data captured from a phase 3 trial suggest pemivibart may be effective prophylaxis against COVID-19 infection for high-risk patients with significant immunocompromising conditions who continue ...

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.

Moby summary of Invivyd, Inc.'s Q4 2025 earnings call ...

Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.

A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

The vaccine plus a booster dose reduces the odds of preeclampsia by 30% and by as much as 58% in those with preexisting ...

The MarketWatch News Department was not involved in the creation of this content. Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to ...